Having trouble accessing articles? Reset your cache.

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy.

The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and Sanofi (Euronext:SAN; NASDAQ:SNY) agreed to terminate Sanofi's ex-U.S. option rights to

Read the full 450 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers